Biotechnology

Alzamend Neuro

Alzamend Neuro released FY2026 Q2 earnings on December 9, 2025 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2959 (forecast USD -1.955)

Alzamend Neuro released FY2026 Semi-Annual earnings on December 9, 2025 (EST), with actual revenue of USD 0 and EPS of USD -1.3331

Alzamend Neuro released FY2026 Q1 earnings on September 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2833 (forecast USD -0.69)

Alzamend Neuro released FY2025 Q4 earnings on July 22 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.4318 (forecast USD -2.7)

Alzamend Neuro released FY2025 annual earnings on July 22 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -11.3245 (forecast USD -11.88)

Alzamend Neuro Initiates Phase 2 Clinical Trial for AL001

Alzamend Neuro Inc. Director Disposes of Common Stock

Alzamend Plans to Launch Five AL001 Phase II Clinical Trials

Alzamend Neuro Starts Phase 2 Clinical Trial for Lithium Treatment of Major Depression at Massachusetts General Hospital

Alzamend Neuro Inc plans to initiate Phase 2 clinical study of AL001 for PTSD in Q4 2025

Alzamend Neuro released FY2025 Q3 earnings on March 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.6954 (forecast USD -3.195)

Alzamend Neuro released FY2025 9 Months Earnings on March 10, 2025 (EST) with actual revenue of USD 0 and EPS of USD -16.5866

Alzamend Neuro Completes Development of Head Coil, AL001 Clinical Trial Upcoming

Alzamend Neuro released FY2025 Q2 earnings on December 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.4697 (forecast USD -3.42)

Alzamend Neuro released FY2025 Semi-Annual Earnings on December 11, 2024 (EST), with actual revenue of USD 0 and EPS of USD -9.7569

Alzamend Neuro released FY2025 Q1 earnings on September 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -11.4214 (forecast USD -21.42)

Alzamend Neuro collaborates with Massachusetts General Hospital for Phase II clinical trial of AL001

Alzamend Neuro collaborates with Massachusetts General Hospital for Phase 2 clinical trial of AL001 for the treatment of Alzheimer's disease

Alzamend Neuro released FY2024 Q4 earnings on July 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -11.1363 (forecast USD -34.2)

Alzamend Neuro released FY2024 Annual Earnings on July 30 (EST), actual revenue USD 0 (forecast USD --), actual EPS USD -132.33 (forecast USD -155.7)

Rich Sparkle

Novabay Pharmac

Valens Semiconductor

Greenpower Motor

Alpha Tech

Offerpad Solutions

VCI Global

Tryhard

Tradr 2X Long APLD Daily ETF

ZeZentalis Pharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Alzamend Neuro(ALZN.US)